Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of recombinant HPV16/18 bivalent vaccine (E. coli) in Chinese women
CTR20131123Phase 2Completed
- Sponsor
- Xiamen University
- Start
- Sep 2015
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of human papillomavirus type 16/18 bivalent vaccine in HPV16 infection (HPV16), human papillomavirus infection type 18, Cervical Cancer (CC), cervical intraepithelial neoplasia (CIN), Anogenital neoplasms, sponsored by Xiamen University. Started Sep 2015; status: completed.
02
Drugs
human papillomavirus type 16/18 bivalent vaccine
03
Conditions
HPV16 infection (HPV16)human papillomavirus infection type 18Cervical Cancer (CC)cervical intraepithelial neoplasia (CIN)Anogenital neoplasms
Beyond the preview
Go deeper on CTR20131123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20131123.